Public Sector Pension Investment Board Acquires 38,839 Shares of Arcus Biosciences, Inc. $RCUS

Public Sector Pension Investment Board lifted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 16.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 269,863 shares of the company’s stock after buying an additional 38,839 shares during the period. Public Sector Pension Investment Board owned approximately 0.25% of Arcus Biosciences worth $3,670,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after acquiring an additional 1,021 shares during the period. SBI Securities Co. Ltd. grew its stake in shares of Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the period. CWM LLC raised its holdings in shares of Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after purchasing an additional 3,810 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after purchasing an additional 1,796 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in Arcus Biosciences by 440.3% during the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after purchasing an additional 6,191 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Trading Down 2.6%

Shares of RCUS stock opened at $18.98 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -5.52 and a beta of 0.84. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $26.40. The firm has a fifty day moving average price of $21.79 and a 200-day moving average price of $18.08.

Insider Buying and Selling

In other Arcus Biosciences news, CEO Terry J. Rosen sold 28,947 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $633,360.36. Following the sale, the chief executive officer owned 2,220,553 shares in the company, valued at approximately $48,585,699.64. This trade represents a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Juan C. Jaen sold 82,997 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $24.71, for a total transaction of $2,050,855.87. Following the transaction, the president directly owned 954,063 shares in the company, valued at $23,574,896.73. This represents a 8.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 265,887 shares of company stock valued at $6,075,020 in the last 90 days. Corporate insiders own 9.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on RCUS. Wells Fargo & Company set a $23.00 target price on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a research report on Thursday, February 12th. The Goldman Sachs Group upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $16.00 to $28.00 in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, January 21st. Wall Street Zen cut Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Finally, Wedbush set a $35.00 target price on Arcus Biosciences and gave the company an “outperform” rating in a report on Wednesday, October 29th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.33.

Arcus Biosciences Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.